Literature DB >> 14677795

Ephedrine-induced cardiac ischemia: exposure confirmed with a serum level.

Joshua G Schier1, Stephen J Traub, Robert S Hoffman, Lewis S Nelson.   

Abstract

The temporal association of symptoms consistent with ephedrine toxicity after ingestion of ephedrine-containing dietary supplements is heavily relied upon to confirm exposure. Few reports in the literature attempt to associate toxicity with serum levels of these drugs. We report a case of ephedrine-induced cardiac ischemia confirmed by a plasma level. A 22-year-old woman ingesting an ephedrine- and caffeine-containing product for 2 days presented with multiple symptoms, including palpitations, nausea, tremulousness, abdominal pain, and vomiting. The initial electrocardiogram (ECG) revealed a normal sinus rhythm with 1 mm of ST segment depression in leads V3 and V4, along with inverted T waves in leads V1-V4. Her symptoms and ST segment depression resolved over several hours with medical management. The amplitude of her T wave inversions notably diminished with therapy; however, they did not completely resolve. Troponins at presentation and the following morning were negative, and an echocardiogram showed only trace tricuspid regurgitation. A serum ephedrine level, drawn approximately 6 to 7 hr after ingestion, was 150 ng/mL. She was discharged from the hospital after being instructed to avoid ephedrine-containing products.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677795     DOI: 10.1081/clt-120025350

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  2 in total

1.  Cardiac troponin T and cardiac dysfunction in extremely low-birth-weight infants.

Authors:  M A Cruz; Y A Bremmer; B O Porter; S D Gullquist; K L Watterberg; H J Rozycki
Journal:  Pediatr Cardiol       Date:  2006 Jul-Aug       Impact factor: 1.655

2.  Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.

Authors:  C Csajka; C A Haller; N L Benowitz; D Verotta
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.